Gilead’s HIV drug shows potential in two mid-stage studies

(Reuters) – Gilead Sciences Inc said its HIV tablet containing tenofovir alafenamide was found better than its approved drug, Stribild, in two mid-stage studies. The company’s shares rose 1.3 percent to $ 106.77 in early trading on the Nasdaq on Wednesday. In one study, 93 percent of patients taking the drug containing tenofovir alafenamide experienced a reduction in HIV virus in their blood, compared with 92 percent of those taking Stribild. In the second study, 91. …
Sexual Health News Headlines – Yahoo! News